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Abstract: Background: Enalapril is often used in the treatment of cardiovascular diseases. Clinical
data suggest that the urinary excretion of enalaprilat, the active metabolite of enalapril, is mediated by
renal transporters. We aimed to identify enalaprilat specificity for renal proximal tubular transporters.
Methods: Baculovirus-transduced HEK293 cells overexpressing proximal tubular transporters were
used to study enalaprilat cellular uptake. Uptake into cells overexpressing the basolateral transporters
OCT2, OAT1, OAT2, or OAT3 and apical transporters OAT4, PEPT1, PEPT2, OCTN1, OCTN2,
MATE1, MATE2k, and URAT1 was compared with mock-transduced control cells. Transport by renal
efflux transporters MRP2, MPR4, P-gp, and BCRP was tested using a vesicular assay. Enalaprilat
concentrations were measured using LC-MS/MS. Results: Uptake of enalaprilat into cells expressing
OAT3 as well as OAT4 was significantly higher compared to control cells. The enalaprilat affinity for
OAT3 was 640 (95% CI: 520–770) µM. For OAT4, no reliable affinity constant could be determined
using concentrations up to 3 mM. No transport was observed for other transporters. Conclusion:
The affinity of enalaprilat for OAT3 and OAT4 was notably low compared to other substrates. Taking
this affinity and clinically relevant plasma concentrations of enalaprilat and other OAT3 substrates
into account, we believe that drug–drug interactions on a transporter level do not have a therapeutic
consequence and will not require dose adjustments of enalaprilat itself or other OAT3 substrates.
Keywords: enalapril; enalaprilat; drug transporters; proximal tubule cell
1. Introduction
With an increase in both the prevalence and incidence of cardiovascular disease over the past
25 years [1], the number of patients who require treatment is rising. Treatment often comprises complex
regimens in which angiotensin-converting-enzyme (ACE) inhibitors are frequently included [2].
Enalapril is an ACE inhibitor used for the treatment of hypertension, heart failure, and chronic kidney
diseases (CKD) and, although it is a commonly prescribed drug, the effect of enalapril therapy shows
significant interindividual variability that is not completely understood [3].
Various physiological processes, including drug metabolism as well as active uptake and efflux by
different transporters, govern the systemic exposure of enalapril and its active metabolite enalaprilat.
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Knowledge about these processes helps to explain variability in effect as well as to better understand
possible drug–drug interactions. Enalapril is used to treat cardiovascular disease and therefore often
used in combination therapy. In theory, this increases the risk of drug–drug interactions and, therefore,
the risk of altered efficacy or toxicity, both of enalapril itself and/or the other drug(s). Many of these
processes governing enalapril’s disposition have been identified and are shown in Figure 1.
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Figure 1. Processes governing absorption, metabolism, and excretion of enalapril and enalaprilat in the
intestine, liver, and kidney. CES1: carboxylesterase 1.
Uptake of enalapril in the small intestine occurs via passive diffusion [4], followed by the entrance
of enalapril in the hepatocyte mediated by the organic anion transporting polypeptides (OATP) 1B1
and 1B3 [5]. In the hepatocyte, enalapril is metabolized via carboxylesterase 1 (CES1) to its active
metabolite enalaprilat [6]. Although enalapril is considered a specific CES1 substrate, conversion of
approximately 32% to enalaprilat by CES2 has also been reported in freshly prepared rat intestinal
homogenate, but no hu an data are available [7]. Following its formation, enalaprilat is transported
into the systemic circulation via multidrug resistance-associated protein 4 (MRP4) [8]. A minority of
enalapril remains untransfor ed and is excreted into bile via multidrug resistance-associated protein
2 (MRP2) [5]. Renal elimination of enalaprilat is thought to occur through both glomerular filtration as
well as tubular secretion (i.e., active transport), as enalaprilat clearance exceeds the clearance of the
glomerular filtration rate marker inulin [9].
The kidney proximal tubule plays a pivotal role in the excretion of both endogenous and exogenous
compounds and many transporters reside in the basolateral and apical membrane of the proximal
tubule cell (Figure 2).
Understandably, changes in the tubular secretion of drugs may alter their systemic concentrations
and thereby their efficacy and/or toxicity. As 50% of enalaprilat is bound to plasma proteins, only half
of the reported clearance of 120 mL/min can be attributed to GFR (Glomerular Filtration Rate),
emphasizing the importance of tubular secretion in the excretion of the remaining 50% [10,11].
This transporter-mediated secretion is assumed to be facilitated by an organic anion transporter (OAT),
as enalaprilat is a weak acid [12] and its excretion is significantly reduced in vivo in the presence
of probenecid, a competitive inhibitor of organic anion transporters [10]. It was recently described
by Ni et al. that the secretion of enalaprilat by the basolateral proximal tubule cells is mediated by
organic anion transporter 3 (OAT3). Based on in vitro experiments, suggestions for possible drug–drug
and drug–herb interactions were made [13]. However, since clinically important interactions with
enalapril have not been reported before, it raises questions about the in vivo relevance of these
findings. Furthermore, the transporters at the apical side of the proximal tubule responsible for
the elimination of enalaprilat into primary urine remain unknown. Here, we aimed to identify the
membrane transporters involved in the renal proximal tubule transport of enalaprilat in order to
explain the interindividual variability in its pharmacokinetics and to understand the near absence of
clinically relevant drug–drug interactions.
Pharmaceutics 2020, 12, 935 3 of 13
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2. Material and Methods
We used human embryonic kidney 293 (HEK293) cells overexpressing transporters known to be
located in the proximal renal tubule to assess in vitro whether a substrate is also an in vivo transporter
substrate [14]. Both a cellular and vesicular assay were used to assess the renal transporter specificity
for enalaprilat. Methods were adapted from. Te Brake et al. (2016) [15].
Materials. Enalaprilat was purchased from Sanbio (Uden, The Netherlands). Model substrates
were used to confirm uptake capacity of each transporter. [3H]-Glycyl-sarcosine (PEPT1/2),
[14C]-Carnitine (OCTN1/2), and [14C]-Metformin (MATE1/2k and OCT2) were purchased from Moravek
Biochemicals (Brea, CA, USA), while 5(6)-Carboxy-2′,7′-dichlorofluorescein (CDCF) (OAT1 and MRP2)
and Urate (URAT1) were purchased at Sigma-Aldrich (St. Louis, MO, USA). [14C]-para-aminohippuric
acid (OAT2), [3H]-Estrone sulfate (OAT3 and BCRP), and [ H]-Dehydro-epiandrosterone sulfate
(MRP4) were purchased from PerkinElmer (Waltham, MA, USA), and [3H]-NMQ from Solvo
Biotechnology (Szeged, Hungary) was used to confirm transport activity of P-gp. D5-enalaprilat
(Toronto Research Chemicals, North York, Ontario, Canada) was used as an internal standard for liquid
chromatography–tandem mass spectrometry (LC-MS/MS) quantification.
Hanks’ balanced salt solution (HBSS) and GlutaMAX high-glucose Dulbecco’s modified Eagle
medium (DMEM) were obtained by Life Technologies Invitrogen (Carlsbad, CA, USA). Fetal bovine
serum (FBS) was purchased from Greiner Bio-One (Sollingen, Germany) and bovine serum albumin
(BSA) was obtained from Roche Diagnostics GmbH (Mannheim, Germany). Sodium butyrate and
HEPES both were purchased from Sigma-Aldrich. BD BioCoat poly–d-lysine-coated 24-well tissue
culture plates were ordered from Corning (New York, NY, USA). High-quality (UPLC/MS)-grade
methanol was purch s d from Boom (Meppel, The Netherlands) and NaOH from Merck (Darmstadt,
Germany). Protein c ncentrations were determined wi h a colorimetric assay kit (Bio-Rad Protein
Assay) from Bio-Rad Laboratories (Hercules, CA, USA).
The recombi ant baculoviruses that cont in the cDNA of human transporter OCT2, OAT1, OAT2,
OAT3, OAT4, BCRP, URAT1, PEPT1, PEPT2, RP2, MRP4, MATE1, MATE2-k, URAT1, BCRP, P-gp,
OCTN1, and OCTN2 downstream of a cytomegalovirus (CMV) promotor were generated by our
departme t. Generation of these vectors took place as previously described [16]. Amino acid sequences
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were the same as those of GenBank accession no. NM_153276.2 for OAT1, NM_006672 for OAT2,
NM_004254.3 for OAT3, NM_018484.3 for OAT4, NM_003058.4 for OCT2, NM_003059.2 for OCTN1,
NM_003060.3 for OCTN2, NM_018242.3 for MATE1, NM_001099646.2 for MATE2k, NM_144585.3 for
URAT1, NM_005073.3 for PEPT1, NM_021082.3 for PEPT2, and NM_004827.2 for BCRP.
Cell line maintenance and transduction: HEK293 cells were maintained at 37 ◦C with 5% CO2
in DMEM containing 10% FBS. After growing to 70% confluence, ~300,000 cells were seeded in
poly-d-lysine-coated 24-well plates in a volume of 400 µL per well. Twenty-four hours after seeding,
cells were transduced with 60 µL recombinant baculovirus to express the transporter of interest.
As transporter specificity was tested in transiently transduced cells, control cells underwent the same
transduction procedure with enhanced yellow fluorescent protein (EYFP) as control (background).
To enhance protein expression, 140 µL DMEM containing sodium butyrate (3 mM final concentration)
was added to each well. Uptake experiments were performed 3 days post transduction.
Identification of enalaprilat transporters: Prior to testing enalaprilat specificity, transporter
functionality was checked using model substrates. For OAT1 and OAT3, this was previously described
by El-Sheikh et al. [17]. For MRP2, MRP4, P-gp, and BCRP, this was described by Lempers et al. [18].
MATE1, MATE2k, and OCT2 specificity were tested by Van der Velden et al. [19] (Table 1). OAT2 and
OAT4 were tested using [14C]-PAH, PEPT1 and PEPT2 using [3H]-Gly-Sar, URAT1 using urate,
and OCTN1 and OCTN2 using [14C]-Carnitine (Supplementary Figure S1). On the day of the
experiment, the culture medium was removed and cells were first washed in order to equilibrate them
to serum-free conditions with 400 µL buffer (HBSS plus 10 mM HEPES, pH 7.4), prewarmed to 37 ◦C.
Uptake was initiated by replacing this solution with 150 µL of fresh transport buffer (HBSS-HEPES,
pH 7.4, except for MATE2k (pH 8.5) and PEPT1 (pH 6), kept at 37 ◦C) supplemented with the 10 µM
enalaprilat solution incubated at 37 ◦C for 10 min.
For practical reasons, MATE1 and MATE2k activity levels were measured in the uptake direction
due to the nature of the cellular assay, even though, in the kidney and liver, the MATEs export organic
cations into the urine and bile, respectively. Furthermore, also OAT4 activity was measured in the
uptake direction, whereas this transporter is a bidirectional transporter in the kidney. To terminate the
reaction, transport buffer was replaced with 400 µL ice-cold HBSS-HEPES buffer containing 0.5% BSA
(m/v), after which the cells were washed twice with ice-cold HBSS-HEPES. To measure the intracellular
enalaprilat concentrations, cells were solubilized in 200 µL 50% methanol. Aliquots were analyzed
using LC-MS/MS.
If cells transfected with a transporter of interest showed statistically significant uptake of enalaprilat
compared to control cells, inhibition of this transport was tested to prove the role of this specific
transporter. This was the case for OAT3 and OAT4. MK571 was used to demonstrate inhibition
of enalaprilat transport as MK571 is an established multidrug resistance protein inhibitor and was
recently demonstrated to be a high-affinity inhibitor for OAT1, OAT2, and OAT3 [20]. To enable
comparison between inhibitory experiments, OAT4 was also inhibited using MK571, although the
inhibitory potential for OAT4 has not been described before. Enalaprilat (10 µM) uptake experiments
were conducted in the presence and absence of a MK571 (10 µM) solution and cells were incubated for
20 min. When significant uptake and inhibition were observed, further experiments were conducted
to determine time-dependent and concentration-dependent transport for the selected transporters.
Time-dependent uptake of enalaprilat (10 µM) was assessed by performing transport assays at various
incubation times, namely 5, 10, 20, 30, 45, and 60 min. Concentration-dependent transport was
determined by performing uptake assays at various concentration ranges (1, 3, 10, 30, 100, 300, 1000,
and 3000 µM) after 20 min of incubation at 37 ◦C. Finally, to determine the inhibitory potency of
enalaprilat on OAT3 transport, 20 nM [3H]-E1S was used as an OAT3 model substrate with increasing
enalaprilat concentrations up to 3000 µM. This experiment was performed in triplicate.
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Table 1. Previously described transporter activity for listed transporters. Fold change for cellular assay
calculated by transport observed in cells transduced with transporter of interest divided by transport
observed in cells transduced with EYFP. Fold change for vesicular assay calculated as transport observed
in vesicles with ATP divided by those with AMP.
Transporter
Model
Substrate
(Assay)
Transport, Approx.
Fold of Control
(p-Value)
Inhibition of
Transport Shown
(Inhibitor)
Reference
OAT1 [
3H]-MTX
(cells)
3 fold (p < 0.05) Yes (probenecid) El Sheikh et al., 2013 [17]
OAT3 [
3H]-MTX
(cells)
3 fold (p < 0.05) Yes (probenecid) El Sheikh et al., 2013 [17]
OCT2 Cycloguanil(cells) 12 fold (p < 0.03)
Yes (multiple,
inhibition of ASP
most significant for
Quinine)
Van der Velden et al.,
2017 [19]
MATE1 Cycloguanil(cells) 4 fold (p < 0.01) -
Van der Velden et al.,
2017 [19]
MATE2K Cycloguanil(cells) 5 fold (p < 0.001) -
Van der Velden et al.,
2017 [19]
MRP2 [
3H]-MTX
(vesicles)
4 fold - Lempers et al., 2016 [18]
MRP4 [
3H]- E217βG
(vesicles)
5 fold - Lempers et al., 2016 [18]
P-GP [
3H]-NMQ
(vesicles)
5 fold - Lempers et al., 2016 [18]
BCRP [
3H]-E1S
(vesicles)
11 fold - Lempers et al., 2016 [18]
Protein concentration: In each transporter assay, the average amount of cellular protein per
transporter transduction was determined to be able to display the results in a standardized way (uptake
in pmol/mg protein/minute). Cells were solubilized in 200 µL 1 M NaOH and protein concentrations
were determined using the Bio-Rad protein assay kit with BSA as a standard.
Specificity for MRP2, MRP4, P-gp, and BCRP. In order to determine enalaprilat specificity for the
efflux transporters MRP2, MRP4, P-gp, and BCRP, a vesicular assay was used. As no transport was
observed but enalaprilat specificity for MRP4 has been previously described [8], experiments were
repeated, applying double transduction in a cellular assay.
Vesicular assay: Uptake of enalaprilat into membrane vesicles was performed as described
previously [21]. In brief, membrane vesicles (7.5 µg) were prewarmed for 1 min at 37 ◦C and
added to PharmTox assay buffer (PharmTox, Nijmegen, The Netherlands) supplemented with 4 mM
ATP or AMP (control) and 10 mM MgCl2 in a final volume of 30 µL. The reaction mixture was
incubated at 37 ◦C for 10 min. Subsequently, samples were transferred to a 0.45 µm MultiScreenHTS
HV filter plate (PVDF, Merck) by using a Multiscreen™ Vacuum Manifold 96-well filtration device
(Millipore, Bedford, MA, USA) and washed twice with PharmTox stop-wash buffer. Vesicles were
lysed with 100 µL 25% ACN and aliquots were analyzed using liquid LC-MS/MS as described below.
Cellular double transduction assay: Cells were cultured and transduced as described above; however,
since enalaprilat is hydrophilic, an uptake transporter (OAT3) had to be incorporated together with
the efflux transport of interest to measure specificity for these efflux transporters in a cellular assay.
Therefore, HEK293 cells were co-transduced with 30 µL recombinant baculovirus expressing OAT3 and
60 µL recombinant baculovirus coding for either MRP2, MRP4, or P-gp. This enables the determination
of a significant reduction in uptake due to the presence of an efflux transporter. This method of
co-transduction was previously described by van der Velden et al. as a valid method to identify efflux
transporter specificity. In their article, they demonstrated a statistically significant decrease in the
uptake of the OCT1 substrate proguanil in cells co-transduced with OCT1 and MATE-2k, compared to
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OCT1 alone [19]. Quantification of enalaprilat: Enalaprilat was quantified with LC-MS/MS, using an
Acquity UPLC (Waters, Milford, MA, USA) coupled to a Xevo TQ-S (Waters) triple quadropole mass
spectrometer. Separation took place using a BEH C18 analytical column (1.7 µm; 50 × 2.1 mm, Acquity
UPLC®, Waters, Ireland). As an internal standard, d5-enalaprilat was used. The following elution
gradient was used: 0–1 min, from 20% B to 80% B; 1–2 min, 100% B; and 2–3 min, 20% B. Solvent A
consisted of 0.1% formic acid in H2O and solvent B consisted of 0.1% formic acid in methanol.
The column temperature was set at 40 ◦C, and the flow rate was 300 µL/min. The effluent from
the UPLC was passed directly into the electrospray ion source. Positive electrospray ionization
was achieved using nitrogen as a desolvation gas with ionization voltage at 1000 Volt. The source
temperature was set at 500 ◦C and argon was used as collision gas. Detection of enalaprilat and the
internal standard was based on isolation of the protonated molecular ion, [M + H]+, and subsequent
MS/MS fragmentations and a multi reaction monitoring (MRM) were carried out. The following MRM
transitions were used: for enalaprilat, m/z 349.1 (parent ion) to m/z 206.1 and 91.0 (both product ions),
and for d5-enalaprilat, m/z 354.2 (parent ion) to m/z 211.1 and 95.9 (both product ions).
Analysis. Data were expressed as means ± standard error of the means (SEM) from three
independent experiments. Statistically significant differences in uptake (p < 0.05) were assessed using
one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc multiple-comparison test
in the case of the initial transporter screen. Mean uptake ratios of substrate specific transport were
calculated by dividing specific transport by control (background transport). To determine statistically
significant differences in uptake between incubation with and without the presence of an inhibitor,
a paired T-test was applied. All statistical analyses were performed using SPSS version 25 (IBM Corp.,
Armonk, NY, USA). To estimate maximum transport velocity (Vmax) and the substrate concentration
at which half of this rate is obtained (Km), concentration-dependent uptake data were fitted to the
Michaelis–Menten equation and calculated using GraphPad Prism Version 5.3 (GraphPad Software Inc,
San Diego, CA, USA). As Vmax values are dependent on the transporter expression in the particular
system used, transport velocity was depicted as percentage of the Vmax. Non-linear regression analysis
was used to calculate IC50 values with GraphPad Prism, with a bottom = 0 constraint. Assuming
competitive inhibition, the inhibition constant (Ki) value was extrapolated from the IC50-values
according to the Cheng–Prusoff equation. Due to the low substrate concentration, the IC50 is equal to
the Ki.
3. Results
By using both a cellular and vesicular assay, we were able to assess the renal transporter specificity
for enalaprilat.
Screening of uptake transporters. HEK293 cells transiently overexpressing one of the uptake
transporters present in the kidney proximal tubule cells [14,22,23] were used to determine the
transporter specificity for enalaprilat. All relevant transporters showed uptake of their model substrate.
For OAT1, OAT3, OCT2, MATE1, MATE2k, MRP2, MRP4, P-gp, and BCRP, this has been previously
described [15,17–19]. OAT2, OAT4, PEPT1, PEPT2, URAT1, OCTN1, and OCTN2 all showed a
significant transport ratio compared to control cells and were thus also considered suitable for testing
enalaprilat specificity (Supplementary Figure S1). Of all tested transporters, only OAT3 (p = 0.014)
and OAT4 (p = 0.006) mediated statistically significant uptake of enalaprilat compared to control cells
(Figure 3).
Inhibition of OAT3- and OAT4-mediated enalaprilat uptake. To confirm specific transport of
enalaprilat by OAT3 and OAT4, uptake experiments were performed with or without the OAT inhibitor
MK571. As shown in Figure 4, uptake of enalaprilat by OAT3 was statistically significantly reduced in
the presence of MK571 (p < 0.05). Uptake of enalaprilat by OAT4 was visually reduced in the presence
of MK571, though this difference was not significant (p = 0.07).
Pharmaceutics 2020, 12, 935 7 of 13
Pharmaceutics 2020, 12, x FOR PEER REVIEW 7 of 13 
 
the IC50-values according to the Cheng–Prusoff equation. Due to the low substrate concentration, the 
IC50 is equal to the Ki. 
3. Results 
By using both a cellular and vesicular assay, we were able to assess the renal transporter 
specificity for enalaprilat. 
Screening of uptake transporters. HEK293 cells transiently overexpressing one of the uptake 
transporters present in the kidney proximal tubule cells [14,22,23] were used to determine the 
transporter specificity for enalaprilat. All relevant transporters showed uptake of their model 
substrate. For OAT1, OAT3, OCT2, MATE1, MATE2k, MRP2, MRP4, P-gp, and BCRP, this has been 
previously described [15,17–19]. OAT2, OAT4, PEPT1, PEPT2, URAT1, OCTN1, and OCTN2 all 
showed a significant transport ratio compared to control cells and were thus also considered suitable 
for testing enalaprilat specificity (Supplementary Figure S1). Of all tested transporters, only OAT3 (p 
= 0.014) and OAT4 (p = 0.006) mediated statistically significant uptake of enalaprilat compared to 
control cells (Figure 3). 
OA
T1
OA
T2
OA
T3
OA
T4
OC
T2
OC
TN
1
OC
TN
2
MA
TE
1
MA
TE
-2k
PE
PT
1
PE
PT
2
UR
AT
1
0
5
10
15
* **
OAT3 p=0.014
OAT4 p=0.006
Up
ta
ke
 ra
tio
 co
m
pa
re
d 
to
 co
nt
ro
l
 
Figure 3. Uptake of enalaprilat was mediated by OAT3 and OAT4 in HEK293 cells transiently 
overexpressing a single uptake transporter. Transport is expressed as ratio of control cells and 
presented as means ± SEM. Data were pooled from three independent experiments. Dotted line 
represents a ratio between transporter and control of 1 (i.e., no active transport). An asterisk indicates 
a statistically significant difference from the control by one-way ANOVA using Dunnett’s post hoc 
test (* p < 0.05, ** p < 0.01). 
Inhibition of OAT3- and OAT4-mediated enalaprilat uptake. To confirm specific transport of 
enalaprilat by OAT3 and OAT4, uptake experiments were performed with or without the OAT 
inhibitor MK571. As shown in Figure 4, uptake of enalaprilat by OAT3 was statistically significantly 
reduced in the presence of MK571 (p < 0.05). Uptake of enalaprilat by OAT4 was visually reduced in 
the presence of MK571, though this difference was not significant (p = 0.07). 
Figure 3. Uptake of enalaprilat was mediated by OAT3 and OAT4 in HEK293 cells transiently
overexpressing a single uptake transporter. Transport is expressed as ratio of control cells and presented
as means ± SEM. Data were pooled from three independent experiments. Dotted line represents a
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Figure 5. Concentration-dependent uptake of enalaprilat by OAT3 and OAT4. Michaelis–Menten
kinetic curves showing the relationship between enalaprilat concentration and transport velocity of
OAT3 and OAT4. For OAT3, a Km value of 640 µM (95% CI 510–770 µM) was observed, whereas
saturation of transport via OAT4 was not reached over the concentration range measured. Transport
velocity is expressed in percentage of maximum velocity and presented as mean ± SEM for each data
point. Data were pooled from three independent experiments.
Inhibitory potency of enalaprilat against OAT3. Transport of [3H]-E1S by OAT3 was determined in
the presence of increasing enalaprilat concentrations. Exposure to enalaprilat concentration-dependently
inhibited the uptake of 3H-E1S with a Ki value of 134 µM (Supplementary Figure S2).
Specificity for MRP2, MRP4, P-gp, and BCRP. For the efflux transporters MRP2, MRP4, BCRP,
and P-gp, of which MRP4 has been described previously as relevant for hepatic efflux of enalaprilat
into the systemic circulation, we tested the specificity of these transporters for enalaprilat in order
to understand apical transport [14]. Using both a vesicular assay as well as a double-transduction
approach in cells, enalaprilat transport by MRP2, MRP4, BCRP, or P-gp did not differ from control cells
or vesicles (Supplementary Figure S3).
4. Discussion
In this study, we assessed the in vitro affinity of enalaprilat for clinically relevant proximal
tubule transporters and showed that transport of enalaprilat is mediated by OAT3 and OAT4.
We also demonstrated a clear decrease in uptake in the presence of the OAT inhibitor MK571, which
confirms our finding that OAT3 and OAT4 are responsible for basolateral uptake and apical efflux of
enalaprilat. To the best of our knowledge, we are the first to report transporter specificity for 16 renal
tubular transporters.
We were able to reliably determine the apparent affinity constant for the uptake transporter OAT3,
whereas this value could not be calculated for OAT4 because saturation of transport did not show
any sign of saturation up to a concentration of 3 mM. A Km of 640 µM demonstrates a relatively low
affinity as compared to other OAT3 substrates, including many cardiovascular drugs that have a much
higher affinity for OAT3 (i.e., furosemide 21.5 µM [24] and rosuvastatin 7.4 µM [25]).
The affinity constant that we report is in the same range as that of Ni et al. (640 vs. 284 µM).
When taking enalapril concomitantly with other OAT3 interacting drugs, suppression of enalaprilat
uptake by the proximal tubule could theoretically be expected, leading to higher serum concentrations.
However, whether this is also relevant for the disposition of enalaprilat depends on both the KI and
the serum concentration of the drug. To further investigate the inhibitory potential of enalaprilat,
the inhibitory potential of enalaprilat on other OAT3 substrates was attested, showing a Ki value of
134 µM.
Although many possible drug–drug and drug–herb interactions are suggested by Ni et al.,
we believe that the low affinity and relatively high IC50 explain the absence of studies in patients
showing an increase in enalaprilat (i.e., as the victim) plasma concentrations or a relevant interaction
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with drugs taken concomitantly with enalapril (i.e., as the perpetrator drug). For example, the IC50
of the high-affinity OAT3 substrate furosemide is 7.3 µM [26] and observed therapeutic plasma
concentrations are around 3.6 µM (total concentration) [27]. After co-administration of furosemide
with enalapril at therapeutic dosages of both drugs (enalapril 10 mg and furosemide 80 mg), only a
non-significant increase in both the enalaprilat Cmax (increase from 34.9 to 38.2 ng/mL) and area under
the curve (AUC) (increase from 369 to 384 ng/mL/h) were observed [28].
However, at high serum concentrations of an OAT3 substrate drug with a strong inhibitory
potency, significantly reduced excretion of enalaprilat is seen. This was demonstrated by the effect of
probenecid pretreatment (1000 mg once daily for 5 days) on enalaprilat PK in healthy volunteers. [10].
Probenecid is a strong OAT3 inhibitor with an IC50 of 4.4 µM [29]. Mean peak enalaprilat serum
concentrations increased statistically significantly after probenecid pretreatment from 62 to 84 ng/mL,
AUC increased by 50%, and mean clearance decreased from 110 to 66 mL/min after a single 20 mg
enalapril dose. Not only pharmacokinetic (PK) parameters were affected—the pharmacodynamics of
enalaprilat were also influenced by probenecid pretreatment as fractional excretions of sodium, calcium,
magnesium, and urate were enhanced. Moreover, the effect of enalaprilat on the standing mean arterial
pressure (MAP) was further enhanced by probenecid pretreatment (95 ± 2 to 83 ± 2 mmHg, p < 0.01).
This suggests possible clinically relevant interactions between enalaprilat and organic anions with a
high affinity for OAT3 as well as at (very) high plasma concentrations.
When taking the observed enalaprilat Cmax and the affinity for OAT3 into account, we believe
that clinically relevant concentrations of enalaprilat do not lead to saturation of OAT3. Moreover,
the risk of influencing the disposition of other OAT3 substrates at the renal tubular level is extremely
small with an IC50 of 135 µM. In heart failure patients, enalapril doses between 2.5 and 10 mg lead to a
Cmax of enalaprilat of approximately 40–110 ng/mL [30]. This corresponds to values of 0.11–0.32 µM,
which is 2000-fold lower than the Km (640µM) and also significantly lower than the IC50 value (135 µM).
Whether the disposition of enalaprilat changes due to the presence of other OAT3 substrates depends
on their plasma concentration and inhibitory potency.
The Km of OAT4 could not be determined, but based on our experiments, it is at least higher
than 1 mM. Little is known about the role of OAT4 in the excretion of exogenous and endogenous
substances. OAT4 is expressed in the apical membrane of the proximal tubule cell, where it operates
as an asymmetric urate transporter, and it has been shown that the transport of substrates by OAT4
is bidirectional [14]. It is responsible for the secretion of organic anions into the lumen and it forms
an entry point for endogenous substances like urate and estrone sulfate into the proximal tubule
cell [31]. Since enalaprilat is an organic anion and OAT3 is responsible for its uptake from plasma
across the basolateral membrane into the proximal tubular cells, we postulate that OAT4 is responsible
for facilitating the apical efflux of enalaprilat into the primary urine.
Although it was described before that enalaprilat is excreted across the hepatic basolateral
membrane by MRP4, we were not able to replicate this finding using two different experimental
designs of which the vesicular transport assay was broadly similar to that described in the paper
by Ferslew et al. [8]. However, minor differences in cell culture and membrane vesicle preparation
protocols were observed. Ferslew et al. used a stably transfected MRP4 HEK293 cell line and used a
different membrane isolation and transport assay protocol. These differences, however, do not explain
the different results obtained. In addition, the transport activity observed was rather low and an
affinity was not reported. Moreover, the hepatic expression of MRP4 is questionable. Drozdzik et al.
could not detect MRP4 protein using LC-MS/MS and reported very low mRNA expression in hepatic
tissue derived from deceased organ donors [32].
5. Limitations
In conclusion, the current study was designed to gain insight into the renal handling of enalaprilat.
By knowing which transporter is responsible for the renal elimination of enalaprilat and its transporter
kinetics, the absence of drug–drug interactions with frequently used cardiovascular drugs could be
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explained. In contrast, though age-related [33] and disease-associated [34] changes were described
to alter transporter expression and pharmacokinetics of drugs, we do not believe that the large
interindividual variability in enalaprilat exposure observed can be explained by variability in OAT3
and/or OAT4 activity. Taking the relatively low affinity of OAT3 and OAT4 into account, the probability
of these factors to influence the disposition of enalaprilat is negligible as plasma concentration will
stay far below the Km value at therapeutic dosages.
Based on our data, we postulate that OAT3 is responsible for the uptake at the basolateral
membrane of the proximal tubules, whereas OAT4 transports enalaprilat into the primary urine.
Because of the low affinity of enalaprilat for both transporters, we do not consider enalaprilat able to
influence the disposition of other OAT3/4 substrates and vice versa. These data can possibly serve
as input for physiologically based pharmacokinetic (PBPK) modeling to improve predictions about
plasma concentrations of enalaprilat in different populations.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/10/935/s1,
Figure S1: Transporters OAT2, OCTN1, OCTN2, PEPT1, PEPT2 and URAT1 show significant uptake of their
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Figure S3: Efflux transporters MRP2, MRP4, P-gp and BCRP did not show transport of enalaprilat.
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Abbreviations
[3H]-E1S [3H]-estrone-sulfate ammonium salt
[3H]-MTX [3H]-methotrexate
[3H]-NMQ [3H]-N-methyl quinidine
ACE angiotensin-converting-enzyme
AUC area under the curve
ANOVA analysis of variance
BSA bovine serum albumin
BCRP breast cancer resistance protein
CDCF carboxy-2′,7′-dichlorofluorescein
CES1 carboxylesterase 1
CI confidence interval
CKD chronic kidney diseases
Cmax maximum serum concentration
CMV cytomegalovirus
DMEM Dulbecco’s modified Eagle medium
E217βG estradiol 17β-d-glucuronide
EYFP enhanced yellow fluorescent protein
FBS fetal bovine serum
HBSS Hanks’ balanced salt solution
HEK293 human embryonic kidney 293
HPLC high-performance liquid chromatography
IC50 half maximal inhibitory concentration
Km substrate concentration at which half of this speed is obtained
LC-MS/MS liquid chromatography-tandem mass spectrometry
MATE1 multidrug and toxin extrusion 1
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MATE2k multidrug and toxin extrusion 2k
MRP2 multidrug resistance-associated protein 2
MRP4 multidrug resistance-associated protein 4
OAT organic anion transporter
OAT1 organic anion transporter 1
OAT3 organic anion transporter 3
OATP organic anion transporting polypeptides
OCT2 organic cation transporter 2
OCTN1 organic cation/carnitine transporter 1
OCTN2 organic cation/carnitine transporter 2
PEPT1 peptide transporter 1
PEPT2 peptide transporter 2
P-gp P-glycoprotein
SEM standard error of the mean
URAT1 urate transporter 1
Vmax maximum transport velocity
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